Liquidia Corporation (LQDA) Cash Flow Statement

The positive OCF/NI ratio in 2026Q2 contrasts sharply with prior quarters where operating cash flow lagged net income, particularly in 2025Q4 when OCF/NI was 3.04 but net income was only $14.6M. This reversal indicates that the recent profitability is increasingly backed by cash collections, likely from the generic treprostinil distribution. However, the large working capital swings, such as a $15.7M positive change in 2026Q2, warrant monitoring for sustainability.

The dramatic improvement in FCF is driven by the 1031% YoY revenue growth from generic treprostinil, which has shifted the company from cash burn to cash generation. However, this trajectory is heavily dependent on the sustainability of generic distribution margins and the timing of YUTREPIA's full launch. Investors should monitor whether FCF can remain positive as legal and commercial expenses escalate.

The low capital expenditure relative to revenue suggests that the PRINT technology manufacturing may not require heavy ongoing investment, but this could change with YUTREPIA's commercial scale-up. The modest D&A of $400K in 2026Q2 implies limited depreciable assets, but future capacity expansion could increase capital needs. The current capex is likely maintenance-level, with growth capex deferred until regulatory clarity.

The large swings in working capital are consistent with the rapid scaling of generic treprostinil sales, which likely involve significant receivables and inventory management. The positive change in 2026Q2 suggests improved collections, but the negative changes in prior quarters indicate cash absorption. This volatility may persist as the company balances distribution agreements and prepares for YUTREPIA launch.

The absence of capital returns is typical for a pre-commercial biotech, but the consistent negative operating cash flow until 2026Q2 underscores the reliance on external funding. The $190.7M cash position provides a cushion, but ongoing litigation and potential YUTREPIA launch costs could deplete it quickly. Management appears to prioritize liquidity over shareholder returns, which is prudent given the legal uncertainties.

The divergence between cumulative net income and operating cash flow suggests that accruals, particularly working capital and non-cash items like SBC, have inflated earnings relative to cash generation. This gap is typical for growth-stage pharma, but the magnitude warrants attention as the company transitions to profitability. The recent positive quarters may signal a reversal, but the historical pattern highlights the need for sustained cash generation.